Literature DB >> 2427137

Italian type of deletional hereditary persistence of fetal hemoglobin.

G Saglio, C Camaschella, A Serra, T Bertero, G Rege Cambrin, A Guerrasio, U Mazza, P Izzo, F Terragni, B Giglioni.   

Abstract

We report a new type of deletion of the beta globin gene cluster in the Italian population that confers a phenotype of hereditary persistence of fetal hemoglobin (HPFH) to the carriers. This deletion begins approximately 5 kilobases (kb) 5' to the delta globin gene and ends approximately 30 kb 3' to the beta globin gene, in close proximity to the 3' end of an Indian HPFH. In all four previously described HPFH, a repetitive Alu I region 5' to the delta globin gene is largely or completely deleted; the 5' end of the new HPFH is consistent with this common feature. In addition, the finding that Italian and Indian HPFHs, as reported for other groups of deletions, have very close 3' ends, strengthens the idea that common mechanisms may operate in generating these deletions. Finally, we show that, in spite of similar 5' breakpoints, the deletion of Spanish delta beta(0)-thalassemia is at least 8 kb longer than that of Negro HPFH type I, thus ruling out the hypothesis that the overall extent of the deletion might influence the level of gamma globin chain synthesis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2427137

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  Multiplex-PCR assay for the deletions causing hereditary persistence of fetal hemoglobin.

Authors:  Urvashi Bhardwaj; Edward R B McCabe
Journal:  Mol Diagn       Date:  2005

2.  Filipino beta zero thalassaemia: a high Hb A2 beta zero thalassaemia resulting from a large deletion of the 5' beta globin gene region.

Authors:  P I Motum; A Kearney; T J Hamilton; R J Trent
Journal:  J Med Genet       Date:  1993-03       Impact factor: 6.318

3.  Detection of non-deletional type of hereditary persistence of fetal hemoglobin (HPFH) condition associated with 619 bp β(°)-thalassemia deletion.

Authors:  S M Husain; M P Anandaraj
Journal:  Indian J Clin Biochem       Date:  1997-07

4.  Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: An approach for treating sickle cell disease and β-thalassemia.

Authors:  Lin Ye; Jiaming Wang; Yuting Tan; Ashley I Beyer; Fei Xie; Marcus O Muench; Yuet Wai Kan
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-06       Impact factor: 11.205

5.  DNA methylation in hereditary persistence of fetal hemoglobin (HPFH-2).

Authors:  M Poncz; M Sutton; K Delgrosso; E Schwartz; S Surrey
Journal:  Nucleic Acids Res       Date:  1987-07-10       Impact factor: 16.971

Review 6.  Manipulation of Developmental Gamma-Globin Gene Expression: an Approach for Healing Hemoglobinopathies.

Authors:  Vigneshwaran Venkatesan; Saranya Srinivasan; Prathibha Babu; Saravanabhavan Thangavel
Journal:  Mol Cell Biol       Date:  2020-12-21       Impact factor: 4.272

7.  RFLPs of the phenylalanine hydroxylase gene in the Italian population.

Authors:  I Dianzani; L Farinasso; P Fortina; C Camaschella; R Ponzone; H H Dahl; R G Cotton; A Ponzone
Journal:  J Inherit Metab Dis       Date:  1989       Impact factor: 4.982

8.  Disrupting the adult globin promoter alleviates promoter competition and reactivates fetal globin gene expression.

Authors:  Sarah K Topfer; Ruopeng Feng; Peng Huang; Lana C Ly; Gabriella E Martyn; Gerd A Blobel; Mitchell J Weiss; Kate G R Quinlan; Merlin Crossley
Journal:  Blood       Date:  2022-04-07       Impact factor: 22.113

9.  Molecular characterization of a novel form of (A gamma delta beta)zero-thalassemia deletion with a 3' breakpoint close to those of HPFH-3 and HPFH-4: insights for a common regulatory mechanism.

Authors:  N P Anagnou; T Papayannopoulou; A W Nienhuis; G Stamatoyannopoulos
Journal:  Nucleic Acids Res       Date:  1988-07-11       Impact factor: 16.971

10.  An enhancer element lies 3' to the human A gamma globin gene.

Authors:  D M Bodine; T J Ley
Journal:  EMBO J       Date:  1987-10       Impact factor: 11.598

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.